Publication
Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial
Journal Paper/Review - Jun 1, 2004
Thürlimann Beat, Rochlitz Christoph, Aebi Stefan, Perey Lucien, Pagani Olivia, Ballabeni Pierluigi, Senn Isabella, Köberle Dieter, Hess Dagmar, Goldhirsch Aron